Another link between CD274/PDL-1 and psoriasis stems from the clinical observation than more than one third of cancer patients treated with Immune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), CD279/PD-1 or CD274/PD-L1 develop cutaneous immune-related adverse events (irAEs), including characteristic psoriasis lesions37. This evidence concerns the gene CTLA4 and psoriasis.